Today: 29 April 2026
PLS Group share price slides on cost jump, Ngungaju restart talk jars investors
30 January 2026
1 min read

PLS Group share price slides on cost jump, Ngungaju restart talk jars investors

Sydney, January 30, 2026, 16:52 AEDT — Market closed.

  • PLS fell 6.5% to A$4.29 at the close after its December-quarter update
  • Revenue rose 49% from the prior quarter, but output dipped and costs climbed
  • A Ganfeng unit filed that it sold 32.19 million shares in an on-market block trade

PLS Group shares ended down 6.5% at A$4.29 on Friday, giving back early gains after the lithium producer flagged higher unit costs and a possible restart of an idled processing plant at its Pilgangoora operations.

The swing matters because lithium names have been trading off a fragile price recovery, and any sign that producers are bringing mothballed capacity back can quickly spook the market. Traders are also looking for proof that higher realised prices are turning into steady cash, not just one-quarter noise.

PLS, formerly Pilbara Minerals, is one of Australia’s biggest producers of spodumene concentrate — mined lithium feedstock used to make battery chemicals. That gives its quarterly numbers outsized weight in a sector still trying to work out whether the downcycle is ending or just pausing.

In its December-quarter report, PLS said production fell 7% from the prior quarter to 208,000 tonnes, while sales rose 8% to 232,000 tonnes. Average estimated realised pricing climbed to US$1,161 a tonne (delivered into China), lifting revenue 49% to A$373 million, while unit operating costs (FOB, or excluding freight and royalties) rose 8% to A$585 a tonne; cash margin from operations was A$166 million and cash at quarter-end stood at A$954 million.

Separately, an ASX filing showed GFL International Co., a unit of China’s Ganfeng Lithium, sold 32.19 million PLS shares in an on-market block trade at A$5 a share and ceased to be a substantial holder.

The stock had looked headed the other way earlier. Shares were up about 4% in morning trade, and managing director Dale Henderson struck an upbeat tone on demand, telling local media: “The near term outlook is looking very positive but we’ll see how we’ll go.” Stockhead

Brokers have been shifting their stance as lithium prices improve. MT Newswires reported this week that Barrenjoey Markets upgraded PLS to “overweight” from “neutral” and set a A$5.50 price target. MarketScreener

Still, there is a clean downside case. If spodumene prices fade again, higher operating costs and any decision to restart capacity could land badly, especially if other producers also move to lift output at the same time. The early rally-and-reversal on Friday is a reminder that this trade is still skittish.

Next up, investors are watching for the board’s call on whether to restart the roughly 200,000-tonne-a-year Ngungaju plant, which PLS said could be brought back within about four months if approved, with a decision expected in the coming quarter.

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Biogen lowered its 2026 adjusted earnings forecast to $14.25–$15.25 per share, citing research and development charges from recent acquisitions. First-quarter revenue rose 2% to $2.48 billion, with adjusted earnings of $3.57 per share, beating analyst estimates. Leqembi sales climbed 74% to $168 million globally.
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
KLA stock whipsaws after earnings; KLAC rebounds in after-hours trade
Previous Story

KLA stock whipsaws after earnings; KLAC rebounds in after-hours trade

Bellevue Gold share price slides 5% as gold tumbles from record highs — what to watch next week
Next Story

Bellevue Gold share price slides 5% as gold tumbles from record highs — what to watch next week

Go toTop